CN104804056A - Sarcopyramis nepalensis extract and application thereof - Google Patents
Sarcopyramis nepalensis extract and application thereof Download PDFInfo
- Publication number
- CN104804056A CN104804056A CN201510205093.6A CN201510205093A CN104804056A CN 104804056 A CN104804056 A CN 104804056A CN 201510205093 A CN201510205093 A CN 201510205093A CN 104804056 A CN104804056 A CN 104804056A
- Authority
- CN
- China
- Prior art keywords
- compound
- extract
- medicine
- sarcopyramis nepalensis
- drug regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
- C07C47/58—Vanillin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/126—Acids containing more than four carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
- C07C57/12—Straight chain carboxylic acids containing eighteen carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/40—Separation, e.g. from natural material; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/02—Monosaccharides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/04—Disaccharides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/08—Deoxysugars; Unsaturated sugars; Osones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J17/005—Glycosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a sarcopyramis nepalensis extract. A preparation method of the sarcopyramis nepalensis extract comprises the following steps: taking whole herb of sarcopyramis nepalensis; after crushing the taken whole herb of the sarcopyramis nepalensis, extracting the crushed whole herb of the sarcopyramis nepalensis with ethyl alcohol of 95% for six times, wherein the extraction time each time is one week; performing the filtration, and performing the concentration so as to obtain a medicinal extract. The extract can be used for medicines for nourishing a liver and reducing transaminase, the sarcopyramis nepalensis extract disclosed by the invention can widely affect all the cytokine levels, pharmacological activities of nourishing the liver and reducing the transaminase are realized through regulating the balance of a cytokine network, and scientific basis is provided for the clinical application of the sarcopyramis nepalensis extract.
Description
Technical field
The invention belongs to chemical field, be specifically related to a kind of Herba Sarcopyramis nepalensis extract and application thereof.
Background technology
Herba Sarcopyramis nepalensis (Sarcopyramis nepalensis Wall.), have another name called Nepal's meat fringe grass, wind drum bucket grass (wind cabinet bucket grass), the meat fringe grass belonged in Melastomataceae (Melastomaceae) belongs to (Sarcopyramis Wall1).Mainly be distributed in the ground such as the Sichuan of South East Asia and China, Yunnan, Hubei, Guangxi, Guangdong, Jiangxi, Taiwan, Fujian.Recording according to " Chinese medicine dictionary ": Herba Sarcopyramis nepalensis herb is pharmaceutically acceptable, have effect that is clearing heat and detoxicating, clearing liver-fire, is the rare rare Chinese herbal medicine of the diseases such as treatment acute hepatitis, cough due to lung-heat, snake head-like infection, innominate toxic swelling, gastro-enteritis.Best to acute hepatitis (hepatitis A, hepatitis B acute phase) curative effect, to chronic hepatitis and hepatitis B virus carriers effective, among the peoplely in Fujian, Hubei etc. widely using, is the extremely valuable natural medicinal plant of one and Chinese herbal medicine resource.System report is had not yet to see to the research of the chemical composition, pharmacologically active, medicine efficacy relation etc. of this plant.For understanding its main chemical compositions contained and protecting liver, lowering enzymes basic substance, this seminar has carried out following experimental study, to providing scientific basis for clinical application.
Summary of the invention
An object of the present invention is the problem of the few and biological activity aspect of the chemical constitution study for solving Herba Sarcopyramis nepalensis, provides a kind of Herba Sarcopyramis nepalensis extract and application thereof.
The invention provides a kind of Herba Sarcopyramis nepalensis extract, get Herba Sarcopyramis nepalensis herb, pulverize rear 95% extraction using alcohol six times, each 1 week, filter, concentrate and obtain medicinal extract.
Further, get described medicinal extract thin up, extract successively with sherwood oil, ethyl acetate and propyl carbinol, obtain petroleum ether extract, acetic acid ethyl ester extract, n-butyl alcohol extract and the water solubles;
Described petroleum ether extract silica gel column chromatography, with petroleum ether-ethyl acetate system gradient elution, separation and purification, recrystallization obtains compound 3, compound 4, compound 9, compound 11 and compound 17;
Described acetic acid ethyl ester extract silica gel column chromatography, with chloroform-methanol system gradient elution, separation and purification, recrystallization obtains compound 1, compound 2, compound 5, compound 6, compound 7, compound 8, compound 10, compound 16 and compound 18;
Described n-butyl alcohol extract comprises compound 12, compound 15 and compound 20;
The described water solubles comprises compound 13, compound 14, compound 19, compound 21, compound 22, compound 23, compound 24, compound 25, compound 26 and compound 27;
Described compound structure is as follows
Further, described medicine or drug regimen comprise above-mentioned Herba Sarcopyramis nepalensis extract.
Further, described medicine or medicine are used for protecting liver, lowering enzymes, suppress liver injury.
Further, described medicine, drug regimen and nursing materials comprise the various auxiliary materials tablet, pill, capsule, oral liquid, injection liquid and the powder injection made that add pharmaceutics and allow.
Beneficial effect of the present invention is: Herba Sarcopyramis nepalensis extract of the present invention can the various cytokine levels of wide influence, by the pharmacologically active regulating the balance of cytokine network to realize protecting liver, lowering enzymes, for its clinical application provides scientific basis.
Embodiment
Hereafter will describe the present invention in detail in conjunction with specific embodiments.It should be noted that the combination of technical characteristic or the technical characteristic described in following embodiment should not be considered to isolated, they can mutually be combined thus be reached better technique effect.
The invention provides a kind of Herba Sarcopyramis nepalensis extract, get Herba Sarcopyramis nepalensis herb, pulverize rear 95% extraction using alcohol six times, each 1 week, filter, concentrate and obtain medicinal extract.
Get described medicinal extract thin up, extract successively with sherwood oil, ethyl acetate and propyl carbinol, obtain petroleum ether extract, acetic acid ethyl ester extract, n-butyl alcohol extract and the water solubles;
Petroleum ether extract silica gel column chromatography, with petroleum ether-ethyl acetate system gradient elution, separation and purification, recrystallization obtains compound 3, compound 4, compound 9, compound 11 and compound 17;
Acetic acid ethyl ester extract silica gel column chromatography, with chloroform-methanol system gradient elution, separation and purification, recrystallization obtains compound 1, compound 2, compound 5, compound 6, compound 7, compound 8, compound 10, compound 16 and compound 18;
N-butyl alcohol extract comprises compound 12, compound 15 and compound 20;
The water solubles comprises compound 13, compound 14, compound 19, compound 21, compound 22, compound 23, compound 24, compound 25, compound 26 and compound 27;
Described compound structure is as follows
Total cream acute toxicity is observed
Regular grade kunming mice 40,22-25g, male and female half and half, after adaptability feeds 1 week, fasting 12 hours before administration, is assigned to the acute oral toxicity test that 4 dosage groups investigate Sarcopyramis nepalensis Wall immediately, often organizes 10, male and female half and half.According to dosage 5mg/kg, 50mg/kg, 500mg/k, 5000mg/kg, gavage, observes the diet of animal in 2 weeks, movable, the situation such as Mao Ze and living or death.
Modeling
CCl
4the foundation of induced mice acute hepatic injury model
CCl
4the preparation of oil solution
Precision measures 0.2mL CCl
4, add 100mL soybean oil with the equivalent method of progressively increasing, stir, be made into 0.2%CCl
4solution.
The preparation of Silymarin rope suspension
Get Yiganling tablet (38.5mg/ sheet), grind, be mixed with 20.0mg/mL with appropriate distilled water for subsequent use.
The foundation of acute hepatic injury model
Get male mice 30, be divided into normal group, model group, silymarin group at random.Silymarin group before modeling with 20.0mg/mL, 0.1mL/10g body weight gavage, every day 1 time, continuous 10d.Normal group and model group equal gavage equal-volume physiological saline, 1h after last administration, except blank group, all the other respectively organize the equal abdominal injection 0.2%CCl of mouse
4oil solution 0.1mL/10g body weight.Normal group abdominal injection equal-volume soybean oil.Before blood sampling, water 12h is can't help in fasting, gets blood in abdominal injection 24h posterior orbit, after leaving standstill 2h, with the centrifugal 15min of 3000r/min, gets upper serum.It is active and win liver that reitman-frankel method measures serum two-story valley third turn of ammonia (GPT/ALT) and serum glutamic oxalacetic transaminase (GOT/AST), and fix by 10% formaldehyde solution, HE dyeing, does check pathological section.
Herba Sarcopyramis nepalensis opposed polarity position protecting liver, lowering enzymes screening active ingredients
Get male mice 80, be divided into Normal group at random, pathological model contrasts, silymarin group, petroleum ether part administration group, ethyl acetate extract administration group, n-butanol portion administration group, water regional administration group, total cream administration group totally 8 groups.Normal group and model control group gavage every day give equal volume 0.5% tween-80 solution; Silymarin group gavage every day gives 200mg/kg/d silymarin, all the other group dosages are converted as raw medicinal herbs is 10g/kg Mouse Weight, successive administration 10 days, after administration 1 in the 10th day is little, Normal group abdominal injection equal volume soybean oil, other organize equal abdominal injection 0.2%CCl
4oil solution, before blood sampling, water 12h is can't help in fasting, gets blood in abdominal injection 24h posterior orbit, after leaving standstill 2h, with the centrifugal 15min of 3000r/min, gets upper serum.Reitman-frankel method measures the active and serum glutamic oxalacetic transaminase (GOT/AST) of gpt (GPT/ALT) in serum and wins liver, and fix by 10% formaldehyde solution, HE dyeing, does check pathological section.
Experimental result
Total cream acute toxicity observations
After gastric infusion, animal appearance and behavior expression are normal, 4 dosage all without any toxic reaction, without-be poisoned to death.Result show dosage up to during 5000mg/kg still without any toxic reaction, think that total cream toxicity rank of the Sarcopyramis nepalensis Wall that the method is extracted is very low or nontoxic, oral safety.
Abdominal injection CCl
4after 24h, the remarkable rising of ALT and AST two kinds of transaminases in pathological model group rat blood serum, liver section HE dyes and shows the pathological change of typical carbon tetrachloride poisoning, and main manifestations is its central band Intermediate Gray liver cell balloon sample pathology companion centrilobular pipe liver cell endochylema cohesion in diffusivity liver lobule.And normal group animal serum transaminase is normal, liver cell structural integrity, liver lobule is high-visible.Pathological model group compares with Normal group significant difference, and this experiment modeling success is described.The results are shown in Table 2.1
Table 2.1 different treatment group to the impact of mice serum AST, ALT (n=10,
)
* p≤0.05 is compared with normal control.
Δ p≤0.05 is compared with model comparison
Herba Sarcopyramis nepalensis opposed polarity position protecting liver, lowering enzymes screening active ingredients the results are shown in Table 2.2, and its HE coloration result is shown in annex one, and under result is tentatively presented at equal crude drug dosage conditions, total cream and n-butanol portion have and necessarily resist CCl
4the effect of induced Acute liver injury.
Herba Sarcopyramis nepalensis opposed polarity position protecting liver, lowering enzymes screening active ingredients result (
)
* p≤0.05 is compared with normal control.
Δ p≤0.05 is compared with model comparison
Herba Sarcopyramis nepalensis extract of the present invention can the various cytokine levels of wide influence, by the pharmacologically active regulating the balance of cytokine network to realize protecting liver, lowering enzymes, for its clinical application provides scientific basis.
Although give some embodiments of the present invention, it will be understood by those of skill in the art that without departing from the spirit of the invention herein, can change embodiment herein.Above-described embodiment is exemplary, should using embodiment herein as the restriction of interest field of the present invention.
Claims (5)
1. a Herba Sarcopyramis nepalensis extract, is characterized in that, gets Herba Sarcopyramis nepalensis herb, pulverizes rear 95% extraction using alcohol six times, each 1 week, filters, concentrate and obtain medicinal extract.
2. Herba Sarcopyramis nepalensis extract as claimed in claim 1, is characterized in that: get described medicinal extract thin up, extract successively with sherwood oil, ethyl acetate and propyl carbinol, obtain petroleum ether extract, acetic acid ethyl ester extract, n-butyl alcohol extract and the water solubles;
Described petroleum ether extract silica gel column chromatography, with petroleum ether-ethyl acetate system gradient elution, separation and purification, recrystallization obtains compound 3, compound 4, compound 9, compound 11 and compound 17;
Described acetic acid ethyl ester extract silica gel column chromatography, with chloroform-methanol system gradient elution, separation and purification, recrystallization obtains compound 1, compound 2, compound 5, compound 6, compound 7, compound 8, compound 10, compound 16 and compound 18;
Described n-butyl alcohol extract comprises compound 12, compound 15 and compound 20;
The described water solubles comprises compound 13, compound 14, compound 19, compound 21, compound 22, compound 23, compound 24, compound 25, compound 26 and compound 27;
Described compound structure is as follows
3. medicine or a drug regimen, is characterized in that, described medicine or drug regimen comprise paper mulberry head extract as claimed in claim 1.
4. medicine as claimed in claim 3 or drug regimen, is characterized in that, described medicine or medicine are used for protecting liver, lowering enzymes, suppress liver injury.
5. medicine as claimed in claim 4 or drug regimen, is characterized in that, described medicine, drug regimen and nursing materials comprise the tablet, pill, capsule, oral liquid, injection liquid and the powder injection that add various auxiliary materials that pharmaceutics allows and make.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510205093.6A CN104804056A (en) | 2015-04-28 | 2015-04-28 | Sarcopyramis nepalensis extract and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510205093.6A CN104804056A (en) | 2015-04-28 | 2015-04-28 | Sarcopyramis nepalensis extract and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104804056A true CN104804056A (en) | 2015-07-29 |
Family
ID=53689282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510205093.6A Pending CN104804056A (en) | 2015-04-28 | 2015-04-28 | Sarcopyramis nepalensis extract and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104804056A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110483488A (en) * | 2019-09-03 | 2019-11-22 | 河南中医药大学 | A kind of isopentene group flavone compound and its preparation method and application |
| CN113501854A (en) * | 2021-06-02 | 2021-10-15 | 广西壮族自治区中国科学院广西植物研究所 | Method for preparing cholesteryl heptadecanoate from slug |
| CN116693591A (en) * | 2022-11-25 | 2023-09-05 | 大理大学 | Preparation and antitumor application of ursane triterpene caffeic acid ester compound |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249117A (en) * | 2008-04-01 | 2008-08-27 | 福建农林大学 | Method for extracting flavonoid from Sarcopyramis nepalensis Wall |
-
2015
- 2015-04-28 CN CN201510205093.6A patent/CN104804056A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249117A (en) * | 2008-04-01 | 2008-08-27 | 福建农林大学 | Method for extracting flavonoid from Sarcopyramis nepalensis Wall |
Non-Patent Citations (2)
| Title |
|---|
| 廖梅等: "楮头红保肝护肝活性部位筛选", 《医药导报》 * |
| 王燕燕等: "楮头红化学成分研究", 《中药材》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110483488A (en) * | 2019-09-03 | 2019-11-22 | 河南中医药大学 | A kind of isopentene group flavone compound and its preparation method and application |
| CN110483488B (en) * | 2019-09-03 | 2021-09-21 | 河南中医药大学 | Isopentenyl flavonoid compound and preparation method and application thereof |
| CN113501854A (en) * | 2021-06-02 | 2021-10-15 | 广西壮族自治区中国科学院广西植物研究所 | Method for preparing cholesteryl heptadecanoate from slug |
| CN113501854B (en) * | 2021-06-02 | 2022-05-17 | 广西壮族自治区中国科学院广西植物研究所 | Method for preparing cholesteryl heptadecanoate from slug |
| CN116693591A (en) * | 2022-11-25 | 2023-09-05 | 大理大学 | Preparation and antitumor application of ursane triterpene caffeic acid ester compound |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102836188B (en) | Folium microcotis total flavone extract and preparation method and application thereof | |
| CN102210724B (en) | Comprehensive utilization of ovate leaf holly bark medicinal material | |
| CN108042627B (en) | Composition for treating hyperuricemia and preparation method and application thereof | |
| CN105832794A (en) | Application of Gynura procumbens to production of medicine, healthcare food or functional food for preventing and treating hyperuricemia | |
| CN103040882B (en) | Passiflora edulis sims stem-leaf extract as well as pharmaceutical composition and antidepressant action of extract | |
| CN104666373A (en) | Novel use of Eurycoma longifolia Jack | |
| CN102134268B (en) | Method for preparing panax japonicus saponin IVa and application of panax japonicus saponin IVa in preparing a medicament for protecting liver and lowering transaminase | |
| CN104804056A (en) | Sarcopyramis nepalensis extract and application thereof | |
| CN101628021A (en) | Preparation method of effective part of radix bupleuri and application thereof | |
| CN104387362B (en) | A kind of iridoidate compound, its preparation method and application | |
| CN101824014A (en) | Compounds with anti-tumor activity in chloranthus japonicus as well as effective parts and purpose thereof | |
| CN101933973B (en) | Medicament composition for preventing and treating liver damage | |
| CN102178721B (en) | Application of fiveleaf gynostemma herb suspension and extract to preparation of drug for treating and resisting depression | |
| CN109674848A (en) | A kind of preparation method and purposes of licorice | |
| CN103271963A (en) | Calliopsis elegans aqueous extract and medical application thereof | |
| CN101040891B (en) | Method of preparing tripterygium hypoglaucum (Levl) hutch alkaloids | |
| CN103816210A (en) | Pueraria lobata extract and application thereof | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN103006781B (en) | Compound Dai medicine extract with liver-protecting effect and preparation method thereof | |
| CN105343350A (en) | Application of Erding granules in preparation of drugs for treating or preventing hyperuricemia and gout diseases | |
| CN101912453B (en) | Medicinal composition with anti-inflammatory and analgesic effects and preparation method and application thereof | |
| CN101214325B (en) | Method for preparing compound 'chenxiangwei'medicine and new use thereof | |
| CN104547026A (en) | Preparation method and application of salvia miltiorrhiza leave and panax pseudo-ginseng extract | |
| CN105267357B (en) | The purposes of Herba Hedyotis Lanceae or its extract | |
| CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150729 |